Tauroursodeoxycholate (dihydrate)

• Description:

  Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771) . Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease[1][2][3][4][5][6][7][8][9][10].

• Product Name Alternative:

  Tauroursodeoxycholic acid (dihydrate) ; TUDCA (dihydrate) ; UR 906 (dihydrate)

• UNSPSC:

  12352211

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Akt; Apoptosis; Caspase; Endogenous Metabolite; IRE1; JNK; NF-κB; Reactive Oxygen Species (ROS)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Metabolic Disease; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/tauroursodeoxycholate-dihydrate.html

• Concentration:

  10mM

• Purity:

  99.96

• Solubility:

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles:

  C[C@H](CCC(NCCS(=O)(O)=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C.O.O

• Molecular Formula:

  C26H49NO8S

• Molecular Weight:

  535.73

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Beuers U. Effects of bile acids on hepatocellular signaling and secretion. Yale J Biol Med. 1997 Jul-Aug;70 (4) :341-6.|[2]Boatright JH, et al. Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor. 2009 Sep;2 (3) :149-159.|[3]Vang S, et al. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob Adv Health Med. 2014 May;3 (3) :58-69. |[4]Benz C, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000 Mar;30 (3) :203-9.|[5]Pike CM, et al. Tauroursodeoxycholic Acid Inhibits Clostridioides difficile Toxin-Induced Apoptosis. Infect Immun. 2022 Aug 18;90 (8) :e0015322.|[6]Shekels LL, et al. Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids. J Lab Clin Med. 1996 Jan;127 (1) :57-66. |[7]Zhang J, et al. Tauroursodeoxycholic Acid Attenuates Renal Tubular Injury in a Mouse Model of Type 2 Diabetes. Nutrients. 2016 Sep 22;8 (10) :589.|[8]Castro-Caldas M, et al. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol Neurobiol. 2012 Oct;46 (2) :475-86. |[9]Wang W, et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018 Feb;175 (3) :469-484.|[10]Xu X, et al. Tauroursodeoxycholic acid alleviates hepatic ischemia reperfusion injury by suppressing the function of Kupffer cells in mice. Biomed Pharmacother. 2018 Oct;106:1271-1281.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  Caspase 3; Caspase 7; Human Endogenous Metabolite; IRE1α

• CAS Number:

  [117609-50-4]